Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism
Churaibhon Wisessaowapak, Yuliya Skorobogatko, Hyeonhui Kim, Xue Feng, Seunghwan Son, Haipeng Fu, Sitao Zhang, Pichaya Lertvilai, Lina Chang, Annie Hoang, Hetty Chen, Sarah Bedsted, Joseph Valentine, Jin Young Huh, Peng Zhao, Shannon M. Reilly, Piyajit Watcharasit, Maryam Ahmadian, Alan R. Saltiel
Churaibhon Wisessaowapak, Yuliya Skorobogatko, Hyeonhui Kim, Xue Feng, Seunghwan Son, Haipeng Fu, Sitao Zhang, Pichaya Lertvilai, Lina Chang, Annie Hoang, Hetty Chen, Sarah Bedsted, Joseph Valentine, Jin Young Huh, Peng Zhao, Shannon M. Reilly, Piyajit Watcharasit, Maryam Ahmadian, Alan R. Saltiel
View: Text | PDF
Research Article Endocrinology Metabolism

A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism

  • Text
  • PDF
Abstract

Metabolic adaptation to both caloric excess and restriction promotes energy conservation by suppressing catabolic pathways via feedback mechanisms that remain incompletely defined. We identified TANK binding kinase 1 (TBK1) as a nutrient- and inflammation-responsive brake on AMPK signaling in adipocytes. Fasting or pharmacological AMPK activation induced Tbk1 transcription via a PGC1α/nuclear respiratory factor 1 axis, which, in turn, limited AMPK activity through a phosphorylation cascade to conserve energy. In obesity, this AMPK/TBK1 axis was disrupted due to chronically elevated basal TBK1, thereby restricting energy expenditure during fasting. Adipocyte-specific TBK1 deletion enhanced fasting-induced AMPK activation, mitochondrial function, and lipolytic gene expression in both lean and obese mice. Pharmacological TBK1 inhibition with amlexanox recapitulated these effects. Combined treatment of mice with amlexanox and the AMPK activator AICAR enhanced weight loss, improved glucose tolerance and insulin sensitivity, and suppressed inflammatory and lipogenic programs in adipose tissue, as well as fibrotic gene expression in the liver. Building on prior clinical observations linking TBK1 inhibition to metabolic health, these findings defined a nutrient-sensitive AMPK/TBK1 feedback loop that limited adipocyte catabolism and suggested that dual targeting of TBK1 and AMPK may help counteract metabolic adaptation and enhance the durability of obesity therapies.

Authors

Churaibhon Wisessaowapak, Yuliya Skorobogatko, Hyeonhui Kim, Xue Feng, Seunghwan Son, Haipeng Fu, Sitao Zhang, Pichaya Lertvilai, Lina Chang, Annie Hoang, Hetty Chen, Sarah Bedsted, Joseph Valentine, Jin Young Huh, Peng Zhao, Shannon M. Reilly, Piyajit Watcharasit, Maryam Ahmadian, Alan R. Saltiel

×

Figure 8

TBK1 loss in adipocytes promotes AMPK activation and mitochondrial OXPHOS expression under nutrient stress.

Options: View larger image (or click on image) Download as PowerPoint
TBK1 loss in adipocytes promotes AMPK activation and mitochondrial OXPHO...
(A–C) WT or ATKO mice subjected to prolonged fasting for 72 hours. Body weight (A), fat mass over 3 days of fasting (B), and iWAT/eWAT weights (C) are shown. n = 5–8, 1-way or 2-way ANOVA with Tukey’s multiple-comparison test. (D) Plasma NEFA and glycerol levels in WT and ATKO mice after 72 hours fasting. n = 5–8, 1-way ANOVA with Tukey’s multiple-comparison test. (E) Quantification of pT172 AMPK/AMPK and pS485 AMPK/AMPK in iWAT from fasted WT and ATKO mice. n = 5–8, 1-way ANOVA with Tukey’s multiple-comparison test. (F and G) WT and ATKO mice fed a 60% kcal HFD for 12 weeks and subjected to 48 hours of fasting. Fat mass was measured by EchoMRI (F), and iWAT/eWAT weights are shown (G). n = 6, 1-way ANOVA with Tukey’s multiple-comparison test. (H) Immunoblot analysis of iWAT from WT and ATKO mice fasted for 48 hours, probed for pS79 ACC, ACC, pT172 AMPK, AMPK, pS172 TBK1, TBK1, and RalA. (I) Quantification of pS79 ACC/ACC and pT172 AMPK/AMPK from H. n = 5, 1-way ANOVA with Tukey’s multiple-comparison test. (J) Immunoblot analysis and quantification of OXPHOS complexes (V–I) in iWAT from WT and ATKO mice fasted for 48 hours. n = 7, 1-way ANOVA with Tukey’s multiple-comparison test. Data are presented as mean ± SEM; each dot represents a biological replicate. **P < 0.01, ***P < 0.001, ****P < 0.0001. ATKO; Tbk1AKO mice.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts